Altimmune Inc.’s ability to start clinical trials for its coronavirus vaccine candidate now lies in the hands of regulators.
The Gaithersburg biotech has submitted its investigational new drug application for its intranasal Covid-19 vaccine, AdCovid, to the Food and Drug Administration, the company said Wednesday. An approval would allow the company to initiate a phase 1 study of the candidate.
Altimmune (NASDAQ: ALT) is on track to kick off that trial in 2020 and report data in the first quarter of 2021, said President and CEO Vipin Garg in a statement. Based on that data, the company “would plan to move swiftly” into a phase 2 clinical trial next year, he told us previously.
Read the full article at: www.bizjournals.com
Latest posts by Chris Frew (see all)
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
- Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
- SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021